How many insider trades does FilingIQ track for HRMY?

FilingIQ tracks 317 Form 4 insider transactions for HRMY (Harmony Biosciences Holdings, Inc.), covering filings from Aug 20, 2020 onwards. 5 of those were filed in the last 90 days.

Are HRMY insiders net buyers or net sellers?

Across the full Form 4 history for HRMY, 8 transactions (3%) were open-market purchases and 179 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does HRMY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is HRMY in?

Harmony Biosciences Holdings, Inc. (HRMY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.60B.

HRMY insider trading

NasdaqGM Healthcare

Harmony Biosciences Holdings, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

317

Last 90 days

Buys / sells

3% / 56%

Market cap

$1.60B

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Company website: www.harmonybiosciences.com

HRMY insider activity at a glance

FilingIQ has scored 317 insider transactions for HRMY since Aug 20, 2020. The most recent filing in our index is dated Apr 7, 2026.

Across the full history, 8 open-market purchases and 179 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on HRMY insider trades is 55.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live HRMY trades on FilingIQ Raw filings on SEC EDGAR

Latest HRMY Form 4 filings

Kapadia Sandip CHIEF FINANCIAL OFFICER

S Aug 15, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for HRMY?: FilingIQ tracks 317 Form 4 insider transactions for HRMY (Harmony Biosciences Holdings, Inc.), covering filings from Aug 20, 2020 onwards. 5 of those were filed in the last 90 days.
Are HRMY insiders net buyers or net sellers?: Across the full Form 4 history for HRMY, 8 transactions (3%) were open-market purchases and 179 (56%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does HRMY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is HRMY in?: Harmony Biosciences Holdings, Inc. (HRMY) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.60B.

Methodology & sources

Every HRMY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.